预约演示
更新于：2025-08-31
Amlodipine Besylate
苯磺酸氨氯地平
更新于：2025-08-31
概要
基本信息
原研机构 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 英国 (1989-03-01), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C26H31ClN2O8S |
InChIKeyZPBWCRDSRKPIDG-UHFFFAOYSA-N |
CAS号111470-99-6 |
关联
502
项与 苯磺酸氨氯地平 相关的临床试验NCT07075965
Calcium Channel Blocker in Myotonic Dystrophy Type 1 (CAP DM1)
CTR20252582
苯磺酸氨氯地平片（5 mg）餐后状态下在健康参与者中的生物等效性试验
NCT06942377
Peking University People's Hospital
100 项与 苯磺酸氨氯地平 相关的临床结果
登录后查看更多信息
100 项与 苯磺酸氨氯地平 相关的转化医学
登录后查看更多信息
100 项与 苯磺酸氨氯地平 相关的专利（医药）
登录后查看更多信息
5,640
项与 苯磺酸氨氯地平 相关的文献（医药）2025-11-01SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY
Fabrication of phytochemical enriched ZnO grafted on few-layered graphene sheets and evaluation of biological and catalytic activity for degradation of medical effluents
Article
作者: Jagan, K S G ; Gopalakrishnan, R ; Savitha, S ; Naren Vidaarth, T M ; Surendhiran, S ; Prabhakaran, M ; Karthik, A
The consumption of contaminated water by humans and animals has resulted in the proliferation of various diseases and environmental pollution. In particular, pharmaceutical effluents are notable as one of the main contaminants in water bodies. Here, zinc oxide nanoparticles (ZnO NPs) were synthesized using Strychnos potatorumseed extract and acted as a reducing and capping agent. Furthermore, the nanocomposite effectively integrated ZnO with reduced graphene oxide (rGO) through reflux. ZnO NPs exhibited a hexagonal wurtzite structure with a crystallite size of 18.3 nm and spherical morphology. The few layers of rGO sheets were wrapped with ZnO NPs, as observed in FESEM images. The surface area was estimated at 28.93 and 103.77 m2/g for ZnO and ZnO-rGO, respectively. Correspondingly, the optical properties of materials correlated with energy gaps of 3.41 and 2.93 eV. The XPS analysis confirms the presence of ZnO-rGO by identifying the distinctive binding energy peaks. The ZnO-rGO nanocomposite exhibited enhanced antibacterial activity, with zones of inhibition measuring 26 mm for S. aureus and 25 mm for E. coli, compared to ZnO NPs. Further, the prepared nanomaterials were used as catalysts to degrade Amlodipine and Metformin drug pollutants under sunlight exposure. ZnO-rGO nanocomposite showed the maximum degradation efficiency of 92.68 % and 95.78 % for Amlodipine and Metformin, respectively. Overall, rGO-wrapped ZnO nanocomposite is versatile for degrading pharmaceutical pollutants and combating bacterial infections.
2025-10-01SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY
Sustainable signal processing spectrophotometric analysis of candesartan, hydrochlorothiazide, and amlodipine: Green methods aligned with global sustainability goals
Article
作者: Lotfy, Hayam Mahmoud ; Obaydo, Reem Hasan ; Genc, Asena Ayse ; Erk, Nevin ; Tiris, Gizem
Green Analytical Chemistry (GAC) aims to create eco-friendly methods for pharmaceutical analysis, with a focus on quality control. This study focuses on the simultaneous quantification of candesartan (CAN), hydrochlorothiazide (HCT), and amlodipine (AML) in a triple medication using two green spectrophotometric techniques. The study incorporates mathematical manipulation approaches to extract the parent spectrum of each drug component. These integrated methods address the problem of spectral signal overlap without requiring prior separation, utilizing a factorized spectrum (FS), which is notable for its capacity to assess the specified drugs in the mixture and retrieve their original zero-order spectra it is distinctive for its ability to evaluate the mentioned drugs within the mixture and recover their initial zero-order spectra. The first integrated resolution technique, the Integrated signal processing plan (ISPP-D0), was applied to the mixture's zero-order spectrum, including successive manipulation of three methods: extended absorbance difference, absorbance resolution, and spectrum subtraction. The second integrated resolution technique is the Integrated signal processing plan (ISPP-R)via ratio spectrum of the mixture, which includes successive manipulation of three methods: dual amplitude difference, ratio extraction, and spectrum subtraction. The proposed methods were validated and assessed following the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) guidelines, showing linear concentration ranges of 5.0-35.0 µg/mL for CAN at 254.0 nm, 2.0-20.0 µg/mL for HCT at 270.0 nm, and 5.0-35.0 µg/mL for AML at 240.0 nm. The specificity was evaluated by accurately and precisely determining the concentrations of the three drugs in their synthetic blends and single-tablet pharmaceutical formulation. The findings were statistically analyzed against the official results using the F-test and Student's t-test, indicating no notable differences. These UV spectrophotometric techniques align with green analytical chemistry (GAC) and white analytical chemistry (WAC) principles, supporting the United Nations Sustainable Development Goals (UNSDGs). These integrated analytical techniques for drug analysis offer enhanced precision and efficiency, enabling the retrieval of zero-order spectra that serve as unique fingerprints for each analyte. These advancements simplify the identification process, improve accuracy, and ensure reliable results, making them invaluable in pharmaceutical research and quality control.
2025-09-14JOURNAL OF LIQUID CHROMATOGRAPHY & RELATED TECHNOLOGIES
An improved ultrasound-assisted extraction (UAE) and HPLC-PDA methods for multiclass analysis of pharmaceutical residues in fish
作者: Ong, M. C. ; Ghazali, A. ; Omar, T. F. T. ; Ibrahim, Y.
This paper presents an improved ultrasound-assisted extraction (UAE) and high-performance liquid chromatog. (HPLC) methods for analyzing amlodipine (AMP), diclofenac (DIC), and simvastatin (SIM) from fish tissue.The method was optimized, validated, and tested with a real sample.Compound separation was achieved using gradient elution on the ZORBAX Eclipse XDB-C18 Narrow Bore Reverse Chromatog. (RR) column, using acetonitrile (ACN)/methanol (MeOH) (60:40 volume/volume) and ultra-pure water as the mobile phases.The UAE method was achieved with ACN/MeOH (60:40 volume/volume) as the extraction solvent, followed by solid-phase extraction (SPE) clean-up, and further concentrated extracts with a rotary evaporator and a nitrogen evaporator.The findings revealed a 74-106% extraction recovery with good precision (%RSD < 16.70).The method is linear with an R2 value of 0.9957-0.9993, sensitive with a detection limit (LOD) of 0.55 to 1.38 ng/g.Method effectiveness was assessed using fish samples from Kuala Dungun, indicating pos. detections of DIC and SIM with mean concentrations of 4.38 ng/g d.w. and 6.22 ng/g d.w., resp.DIC and SIM were ubiquitously detected in all the samples, with DIC exhibiting the highest concentrationHence, the developed method offers a valuable tool for AMP, SIM, and DIC monitoring in fish tissues, facilitating monitoring studies related to pharmaceutical contamination in aquatic environments.
100 项与 苯磺酸氨氯地平 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 吞咽障碍 | 加拿大 | 2019-01-11 | |
| 心绞痛 | 英国 | 1990-01-01 | |
| 变异型心绞痛 | 英国 | 1990-01-01 | |
| 稳定型心绞痛 | 英国 | 1990-01-01 | |
| 冠心病 | 英国 | 1990-01-01 | |
| 高血压 | 英国 | 1989-03-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 难治性高血压 | 临床3期 | 美国 | 2007-10-01 | |
| 难治性高血压 | 临床3期 | 比利时 | 2007-10-01 | |
| 难治性高血压 | 临床3期 | 加拿大 | 2007-10-01 | |
| 难治性高血压 | 临床3期 | 丹麦 | 2007-10-01 | |
| 难治性高血压 | 临床3期 | 芬兰 | 2007-10-01 | |
| 难治性高血压 | 临床3期 | 法国 | 2007-10-01 | |
| 难治性高血压 | 临床3期 | 荷兰 | 2007-10-01 | |
| 难治性高血压 | 临床3期 | 挪威 | 2007-10-01 | |
| 难治性高血压 | 临床3期 | 菲律宾 | 2007-10-01 | |
| 难治性高血压 | 临床3期 | 南非 | 2007-10-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 166 | (Diuretic) | 積廠鹽觸壓繭醖觸遞積(顧窪築範範製壓選齋觸) = 襯網鑰窪夢憲網襯觸選 淵顧鬱觸繭網願積繭鹹 (網繭鏇願願廠襯壓鬱鹹, 8.4) 更多 | - | 2025-07-29 | ||
(Calcium-channel Blocker) | 積廠鹽觸壓繭醖觸遞積(顧窪築範範製壓選齋觸) = 鏇憲醖齋蓋鹹齋衊鑰願 淵顧鬱觸繭網願積繭鹹 (網繭鏇願願廠襯壓鬱鹹, 9.2) 更多 | ||||||
临床2期 | 15 | 夢網顧遞淵醖觸繭積艱(鬱鏇襯鏇糧鏇壓鏇鹽鏇) = 齋獵廠觸鹽廠願鑰窪夢 齋衊鹽繭糧範膚襯齋範 (憲簾壓憲網壓壓築遞鹽, 4.94) 更多 | - | 2025-04-15 | |||
临床4期 | 90 | 網簾構糧襯獵觸鹽顧鏇(蓋製獵廠鬱齋簾齋構鏇) = 壓製齋齋膚獵顧鹹窪醖 鹹鑰範築積遞壓餘憲糧 (選夢鬱憲鏇築範構蓋醖, 10.5) 更多 | - | 2025-03-19 | |||
临床4期 | 301 | (Combination Therapy Phase Nebivolol 5mg/Amlodipine 5 or 10 mg) | 鹹鹹顧淵鹹醖繭築簾製(構鏇鑰願遞襯鑰夢願網) = 製齋廠夢膚鏇簾構簾顧 鬱鏇襯衊遞醖獵夢襯齋 (衊壓襯願衊夢憲鑰壓衊, 8.32) | - | 2025-02-04 | ||
Nebivolo (Nebivolo 5 mg MONOTHERAPY PERIOD) | 餘繭襯築鏇蓋鬱鬱築構(鹽壓觸餘製餘積廠鹽壓) = 餘鑰糧鏇獵顧築築夢積 艱蓋淵願願構糧鏇鏇憲 (糧餘選蓋繭鹽遞鬱觸鹽, 構鹹鹹鬱獵憲夢鹽鬱鬱 ~ 鹽獵衊鹹夢鹹顧襯構蓋) 更多 | ||||||
临床4期 | 175 | 鬱選壓糧鏇鹽醖膚積淵(觸獵齋鏇醖積願鹹範獵) = 蓋遞糧鏇願顧製製糧構 餘鹽積齋蓋願艱蓋憲網 (糧築簾築鑰鹽壓遞鬱蓋, -8.00 ~ 6.00) | 积极 | 2024-12-01 | |||
鬱選壓糧鏇鹽醖膚積淵(觸獵齋鏇醖積願鹹範獵) = 鹽膚窪鏇糧鬱淵淵衊願 餘鹽積齋蓋願艱蓋憲網 (糧築簾築鑰鹽壓遞鬱蓋, -8.00 ~ 6.00) | |||||||
临床4期 | 175 | (Amlodipine) | 糧觸繭鑰鬱壓選簾鑰餘(餘醖鏇廠獵鑰積網鬱廠) = 願鹽製窪鏇網糧蓋範製 積獵鹽衊醖蓋鹽艱範壓 (觸蓋選鹽簾築構遞積蓋, 窪網廠憲窪齋鹽獵製鹽 ~ 齋選襯夢製淵繭構窪鹹) 更多 | - | 2024-10-28 | ||
(Nifedipine ER) | 糧觸繭鑰鬱壓選簾鑰餘(餘醖鏇廠獵鑰積網鬱廠) = 顧窪鏇衊壓選網糧觸遞 積獵鹽衊醖蓋鹽艱範壓 (觸蓋選鹽簾築構遞積蓋, 膚顧淵憲鑰遞繭製醖憲 ~ 獵網淵餘鑰餘遞鑰願壓) 更多 | ||||||
临床3期 | 428 | 壓鹽鏇糧鬱鹹簾簾憲廠(構鏇顧鏇構遞顧製構窪) = 餘積鹹製醖醖艱鏇簾廠 鑰糧鬱襯願艱選鬱醖網 (繭製淵遞遞夢鑰顧鑰構, 12.35) | 积极 | 2024-06-01 | |||
壓鹽鏇糧鬱鹹簾簾憲廠(構鏇顧鏇構遞顧製構窪) = 鏇鏇鏇餘鬱鹹憲衊鑰製 鑰糧鬱襯願艱選鬱醖網 (繭製淵遞遞夢鑰顧鑰構, 12.78) | |||||||
N/A | - | 213 | Indapamide/Amlodipine 1.5/5 mg SPC | 獵鑰築鹽鏇衊糧網窪衊(網觸選構鑰構繭齋憲窪) = observed in 4 patients (2.16%) 獵製糧繭壓壓鬱構糧願 (鬱淵網窪獵憲積鏇襯齋 ) 更多 | 积极 | 2024-05-01 | |
临床4期 | 205 | Standard amlodipine doses (5 and 10 mg) | 遞製觸顧廠觸遞範構選(醖鑰憲選衊糧網積築簾) = 醖鬱壓築蓋艱範衊齋膚 糧蓋築餘窪範獵壓獵觸 (製築築願醖鑰網網淵艱, 6 ~ 7) | 积极 | 2024-02-20 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用